STE 301

Drug Profile

STE 301

Alternative Names: STE-301

Latest Information Update: 10 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stemergie Biotechnology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Electron transport complex I inhibitors; Electron transport complex III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Preclinical Glioma

Most Recent Events

  • 10 Aug 2016 STE 301 is available for licensing as of 10 Aug 2016. http://www.stemergie.com/
  • 10 Aug 2016 Preclinical trials in Glioma in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top